A Trial of Telmisartan Prevention of Cardiovascular Disease
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The present research is conducted as a randomized, parallel-group, controlled, open study
(using the PROBE method) to primarily verify the effects on various biomarkers in high-risk
hypertensive patients treated with ARB (telmisartan, ARB group) as compared with those in
patients receiving ordinary therapy (non-ARB group (ordinary therapy group)). In addition,
onset of cardiovascular events and levels of markers that are associated with cardiovascular
events are observed over time to examine the significance of each marker. The biomarkers will
be obtained at the start of the study (at registration), after 6, 12, 24 and 36 months from
the start of the study.